PDF(Pubmed)
Abstract：
Genomic mutations impact non-small cell lung cancer (NSCLC) biology. The influence of sex and age on the distribution of these alterations is unclear. We analyzed circulating-tumor DNA from individuals with advanced NSCLC from March 2018 to October 2020. EGFR, KRAS, ALK, ROS1, BRAF, NTRK, ERBB2, RET, MET, PIK3CA, STK11, and TP53 alterations were assessed. We evaluated the differences by sex and age (<70 and ≥70) using Fisher\'s exact test. Of the 34,277 samples, 30,790 (89.83%) had a detectable mutation and 19,923 (58.12%) had an alteration of interest. The median age of the ctDNA positive population was 69 (18-102), 16,756 (54.42%) were female, and 28,835 (93.65%) had adenocarcinoma. Females had more alterations in all the assessed EGFR mutations, KRAS G12C, and ERBB2 ex20 ins. Males had higher numbers of MET amp and alterations in STK11 and TP53. Patients <70 years were more likely to have alterations in EGFR exon 19 del/exon 20 ins/T790M, KRAS G12C/D, ALK, ROS1, BRAF V600E, ERBB2 Ex20ins, MET amp, STK11, and TP53. Individuals ≥70 years were more likely to have alterations in EGFR L861Q, MET exon 14 skipping, and PIK3CA. We provided evidence of sex- and age-associated differences in the distribution of genomic alterations in individuals with advanced NSCLC.
摘要：
基因组突变影响非小细胞肺癌（NSCLC）生物学。性别和年龄对这些改变分布的影响尚不清楚。我们分析了2018年3月至2020年10月晚期NSCLC患者的循环肿瘤DNA。EGFR,KRAS,ALK,ROS1,BRAF,NTRK,ERBB2、RET、MET,PIK3CA,评估了STK11和TP53的改变。我们使用Fisher精确检验评估了性别和年龄（<70和≥70）的差异。在34,277个样本中,30,790(89.83%)具有可检测的突变,并且19,923(58.12%)具有感兴趣的改变。ctDNA阳性人群的中位年龄为69（18-102），16,756（54.42%）为女性，腺癌28,835例(93.65%)。女性在所有评估的EGFR突变中有更多的改变，KRASG12C,和ERBB2ex20ins。男性在STK11和TP53中的METamp和改变数量较高。<70岁的患者更可能有EGFR外显子19del/外显子20ins/T790M的改变，KRASG12C/D,ALK,ROS1,BRAFV600E,ERBB2Ex20ins,METamp,STK11和TP53。≥70岁的个体更有可能在EGFRL861中发生改变，MET14外显子跳跃，PIK3CA我们提供了晚期NSCLC患者基因组改变分布中性别和年龄相关差异的证据。
